BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19825952)

  • 21. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
    Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.
    Lu Y; Li X; Liang K; Luwor R; Siddik ZH; Mills GB; Mendelsohn J; Fan Z
    Cancer Res; 2007 Sep; 67(17):8240-7. PubMed ID: 17804738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stabilization of mammary-derived growth inhibitor messenger RNA by antiestrogens.
    Huynh H; Pollak M
    Clin Cancer Res; 1997 Nov; 3(11):2151-6. PubMed ID: 9815609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracytoplasmic epidermal growth factor receptor shows poor response to the cetuximab antitumor effect in irradiated non-small cell lung cancer cell lines.
    Ryu SH; Lee SW; Yang YJ; Song SY; Kim JH; Choi EK; Ahn SD
    Lung Cancer; 2012 Sep; 77(3):482-7. PubMed ID: 22704525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms.
    Garrido G; Rabasa A; Garrido C; López A; Chao L; García-Lora AM; Garrido F; Fernández LE; Sánchez B
    Oncogene; 2014 Jun; 33(24):3129-39. PubMed ID: 23975426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.
    Aerts HJ; Dubois L; Hackeng TM; Straathof R; Chiu RK; Lieuwes NG; Jutten B; Weppler SA; Lammering G; Wouters BG; Lambin P
    Radiother Oncol; 2007 Jun; 83(3):326-32. PubMed ID: 17531336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumour activity of S-1 in combination with cetuximab on human gastric cancer cell lines in vivo.
    Kobunai T; Watanabe T; Fukusato T
    Anticancer Res; 2011 Nov; 31(11):3691-6. PubMed ID: 22110188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor.
    Diaz A; Batista AE; Montero E
    J Interferon Cytokine Res; 2009 Aug; 29(8):433-40. PubMed ID: 19514842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of mammary-derived growth inhibitor gene expression by growth hormone and insulin-like growth factor I.
    Huynh H; Beamer W
    Int J Oncol; 1998 Sep; 13(3):577-82. PubMed ID: 9683796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of EGFR expression level and cetuximab activity in patient-derived xenograft models of human non-small cell lung cancer.
    Amendt C; Staub E; Friese-Hamim M; Störkel S; Stroh C
    Clin Cancer Res; 2014 Sep; 20(17):4478-87. PubMed ID: 24947928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody.
    Hu S; Dai H; Zhang T; Fu W; Berezov SD; Chen C; Jorissen D; Takeda H; Bethune AN
    Cancer Lett; 2015 Feb; 357(1):374-383. PubMed ID: 25434797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization and cancer cell specific binding properties of anti-EGFR antibody conjugated quantum dots.
    Lee J; Choi Y; Kim K; Hong S; Park HY; Lee T; Cheon GJ; Song R
    Bioconjug Chem; 2010 May; 21(5):940-6. PubMed ID: 20420360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered Expression of Three EGFR Posttranslational Regulators MDGI, MIG6, and EIG121 in Invasive Breast Carcinomas.
    Meseure D; Drak Alsibai K; Vacher S; Hatem R; Nicolas A; Callens C; Lerebours F; Bieche I
    Anal Cell Pathol (Amst); 2020; 2020():9268236. PubMed ID: 32377505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays.
    Smith MA; Hall R; Fisher K; Haake SM; Khalil F; Schabath MB; Vuaroqueaux V; Fiebig HH; Altiok S; Chen YA; Haura EB
    Sci Signal; 2015 Jan; 8(359):ra4. PubMed ID: 25587191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A monoclonal antibody targeting the dimer interface of epidermal growth factor receptor (EGFR).
    Guo T; Zhao L; Zhang Y; Liu G; Yao Y; Li H
    Immunol Lett; 2016 Dec; 180():39-45. PubMed ID: 27816480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mammary-derived growth inhibitor (MDGI) cloned from human breast epithelial cells is expressed in fully differentiated lobular structures.
    Hu Y; Russo I; Ao X; Russo J
    Int J Oncol; 1997 Jul; 11(1):5-11. PubMed ID: 21528173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.
    Liao HW; Hsu JM; Xia W; Wang HL; Wang YN; Chang WC; Arold ST; Chou CK; Tsou PH; Yamaguchi H; Fang YF; Lee HJ; Lee HH; Tai SK; Yang MH; Morelli MP; Sen M; Ladbury JE; Chen CH; Grandis JR; Kopetz S; Hung MC
    J Clin Invest; 2015 Dec; 125(12):4529-43. PubMed ID: 26571401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermal growth factor receptor targeting alters gene expression and restores the adhesion function of cancerous cells as measured by single cell force spectroscopy.
    Azadi S; Tafazzoli-Shadpour M; Omidvar R; Moradi L; Habibi-Anbouhi M
    Mol Cell Biochem; 2016 Dec; 423(1-2):129-139. PubMed ID: 27696309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of the novel human breast cancer growth inhibitor, mammary-derived growth inhibitor-related gene, MRG.
    Shi YE; Ni J; Xiao G; Liu YE; Fuchs A; Yu G; Su J; Cosgrove JM; Xing L; Zhang M; Li J; Aggarwal BB; Meager A; Gentz R
    Cancer Res; 1997 Aug; 57(15):3084-91. PubMed ID: 9242429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.
    Desnoyers LR; Vasiljeva O; Richardson JH; Yang A; Menendez EE; Liang TW; Wong C; Bessette PH; Kamath K; Moore SJ; Sagert JG; Hostetter DR; Han F; Gee J; Flandez J; Markham K; Nguyen M; Krimm M; Wong KR; Liu S; Daugherty PS; West JW; Lowman HB
    Sci Transl Med; 2013 Oct; 5(207):207ra144. PubMed ID: 24132639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.